Francois Brisebois
Stock Analyst at Oppenheimer
(2.33)
# 1,175
Out of 4,667 analysts
84
Total ratings
44.44%
Success rate
-2.01%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $63 → $65 | $46.58 | +39.54% | 6 | Nov 14, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $17.93 | +56.16% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $10.75 | +179.07% | 8 | Oct 31, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $73.68 | +121.23% | 4 | Oct 31, 2024 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Outperform | $56 → $59 | $32.79 | +79.93% | 5 | Oct 30, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $29.99 | +83.39% | 5 | Sep 3, 2024 | |
| KALA KALA BIO | Reiterates: Outperform | $15 | $6.43 | +133.28% | 2 | Aug 19, 2024 | |
| DMAC DiaMedica Therapeutics | Reiterates: Outperform | $6 | $4.02 | +49.25% | 5 | Aug 16, 2024 | |
| ACHV Achieve Life Sciences | Reiterates: Outperform | $11 | $4.31 | +155.52% | 6 | Aug 15, 2024 | |
| CNTA Centessa Pharmaceuticals | Reiterates: Outperform | $14 | $16.74 | -16.37% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $15 | $3.13 | +379.23% | 4 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $6.17 | +305.19% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $27.58 | +135.68% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 → $20 | $7.52 | +165.96% | 3 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $4.76 | +110.08% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.90 | +453.34% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $11.16 | +1,262.01% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $16.78 | +114.54% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $1.55 | +158.90% | 3 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.91 | +6,493.41% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $90 | $0.21 | +42,879.94% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 | $0.50 | +904.02% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8.5 | $4.74 | +79.51% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $6.03 | +82.42% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $1.62 | +1,011.11% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $4.66 | +972.96% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $2.96 | +109,359.46% | 1 | Feb 4, 2020 |
Tarsus Pharmaceuticals
Nov 14, 2024
Maintains: Outperform
Price Target: $63 → $65
Current: $46.58
Upside: +39.54%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $17.93
Upside: +56.16%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $10.75
Upside: +179.07%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $73.68
Upside: +121.23%
Harmony Biosciences Holdings
Oct 30, 2024
Reiterates: Outperform
Price Target: $56 → $59
Current: $32.79
Upside: +79.93%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $29.99
Upside: +83.39%
KALA BIO
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $6.43
Upside: +133.28%
DiaMedica Therapeutics
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $4.02
Upside: +49.25%
Achieve Life Sciences
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.31
Upside: +155.52%
Centessa Pharmaceuticals
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $16.74
Upside: -16.37%
Jun 26, 2024
Maintains: Outperform
Price Target: $11 → $15
Current: $3.13
Upside: +379.23%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $6.17
Upside: +305.19%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $27.58
Upside: +135.68%
May 13, 2024
Reiterates: Outperform
Price Target: $29 → $20
Current: $7.52
Upside: +165.96%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $4.76
Upside: +110.08%
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.90
Upside: +453.34%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $11.16
Upside: +1,262.01%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $16.78
Upside: +114.54%
Apr 4, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $1.55
Upside: +158.90%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.91
Upside: +6,493.41%
Feb 6, 2023
Maintains: Outperform
Price Target: $120 → $90
Current: $0.21
Upside: +42,879.94%
Oct 3, 2022
Upgrades: Outperform
Price Target: $5
Current: $0.50
Upside: +904.02%
Sep 7, 2022
Initiates: Outperform
Price Target: $8.5
Current: $4.74
Upside: +79.51%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $6.03
Upside: +82.42%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $1.62
Upside: +1,011.11%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $4.66
Upside: +972.96%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $2.96
Upside: +109,359.46%